CHI3L1

Chitinase 3-like 1 (cartilage glycoprotein-39)

PDB rendering based on 1hjv.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols CHI3L1 ; ASRT7; CGP-39; GP-39; GP39; HC-gp39; HCGP-3P; YKL-40; YKL40; YYL-40; hCGP-39
External IDs OMIM: 601525 MGI: 1340899 HomoloGene: 55569 GeneCards: CHI3L1 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 1116 12654
Ensembl ENSG00000133048 ENSMUSG00000064246
UniProt P36222 Q61362
RefSeq (mRNA) NM_001276 NM_007695
RefSeq (protein) NP_001267 NP_031721
Location (UCSC) Chr 1:
203.18 – 203.19 Mb
Chr 1:
134.18 – 134.19 Mb
PubMed search

Chitinase-3-like protein 1 (CHI3L1), also known as YKL-40, is a secreted glycoprotein that is approximately 40kDa in size that in humans is encoded by the CHI3L1 gene.[1][2][3] The name YKL-40 is derived from the three N-terminal amino acids present on the secreted form and its molecular mass. YKL-40 is secreted by various cell-types including macrophages, chondrocytes, and some types of cancer cells. YKL-40 lacks chitinase activity due to mutations within the active site (conserved sequence: DXXDXDXE ; YKL-40 sequence: DGLDLAWL). The exact physiological role of YKL-40 is not known, but it has been implicated in development, inflammatory disease (such as asthma,[4] and cancer progression).

Function

Chitinases catalyze the hydrolysis of chitin, which is an abundant glycopolymer found in insect exoskeletons and fungal cell walls. The glycoside hydrolase 18 family of chitinases includes eight human family members. This gene encodes a glycoprotein member of the glycosyl hydrolase 18 family. The protein lacks chitinase activity and is secreted by activated macrophages, chondrocytes, neutrophils and synovial cells. The protein is thought to play a role in the process of inflammation and tissue remodeling.[3]

Regulation and mechanism

YKL-40 has been linked to activation of the AKT pro-survival (anti-apoptotic) signaling pathway.[5]

YKL-40 is a migration factor for primary astrocytes and its expression is controlled by NFI-X3, STAT3, and AP-1.[6]

Role in cancer

YKL-40 is a Th2 promoting cytokine that is present at high levels in the tumor micro-environment and in the serum of cancer patients.[7][8] Elevated levels of YKL-40 correlate strongly with stage and outcome of various types of cancer, which establish YKL-40 as a biomarker of disease severity.[9] Targeting YKL-40 with neutralizing antibodies has been proven effective as a treatment in animal models of glioblastoma multiforme.[10] YKL-40 is able to promote angiogenesis through VEGF-dependent and independent pathways.[5]

YKL-40 also enhances tumor survival in response to gamma-irradiation.[5]

References

  1. Hakala BE, White C, Recklies AD (Jan 1994). "Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family". J Biol Chem 268 (34): 25803–10. PMID 8245017.
  2. Rehli M, Krause SW, Andreesen R (Sep 1997). "Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation". Genomics 43 (2): 221–5. doi:10.1006/geno.1997.4778. PMID 9244440.
  3. 1 2 "Entrez Gene: CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39)".
  4. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, Radford S, Parry RR, Heinzmann A, Deichmann KA, Lester LA, Gern JE, Lemanske RF, Nicolae DL, Elias JA, Chupp GL (April 2008). "Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function". N. Engl. J. Med. 358 (16): 1682–91. doi:10.1056/NEJMoa0708801. PMC 2629486. PMID 18403759.
  5. 1 2 3 Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, Moral L, Yan W, Bentley B, Shao R (April 2011). "Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma". J. Biol. Chem. 286 (17): 15332–43. doi:10.1074/jbc.M110.212514. PMC 3083166. PMID 21385870.
  6. Singh SK, Bhardwaj R, Wilczynska KM, Dumur CI, Kordula T (November 2011). "A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40". J. Biol. Chem. 286 (46): 39893–903. doi:10.1074/jbc.M111.257451. PMC 3220556. PMID 21953450.
  7. Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH (2009). "YKL-40 tissue expression and plasma levels in patients with ovarian cancer". BMC Cancer 9: 8. doi:10.1186/1471-2407-9-8. PMC 2645422. PMID 19134206.
  8. Bernardi D, Padoan A, Ballin A, Sartori M, Manara R, Scienza R, Plebani M, Della Puppa A (April 2012). "Serum YKL-40 following resection for cerebral glioblastoma". J. Neurooncol. 107 (2): 299–305. doi:10.1007/s11060-011-0762-7. PMID 22102082.
  9. Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL (July 2003). "High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival". Breast Cancer Res. Treat. 80 (1): 15–21. doi:10.1023/A:1024431000710. PMID 12889595.
  10. Faibish M, Francescone R, Bentley B, Yan W, Shao R (May 2011). "A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers". Mol. Cancer Ther. 10 (5): 742–51. doi:10.1158/1535-7163.MCT-10-0868. PMC 3091949. PMID 21357475.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia - version of the Wednesday, April 29, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.